New human drug trials that may pave the way to treat the underlying biochemistry of learning disabilities are currently underway. The drug trials involve use of a familiar class of drugs known as statins, which up to now have been widely used for treatment of high cholesterol. As reported in the Los Angeles Times, the trials originate from researchers at UCLA.
The technical details of the research appear in the November issue of Current Biology.
The current hypothesis is that statin drugs will remedy the effects of a genetic defect that has been associated with learning disabilities. In experimental models using the drug, it has shown signs of improving the following: poor attention spans, difficulties carrying out tasks involving spatial abilities, and problems learning new tasks.
This news has the potential to significantly change the current medical treatment for learning disabilities. While some parents may be willing to immediately embrace this potential new medical regime, others may be more cautious and skeptical. Fortunately, IDEA 2004 has a new provision that prohibits schools from requiring parents to engage in drug treatment as a condition of attending school, being evaluated, or receiving services. (See the .pdf version of 20 U.S.C. sec. 1412(25), also referred to as section 612(25).) Parents should not allow schools to bully them into drug treatments. Drug treatments should be pursued only when you are ready, and in accordance with the advice of a physician (as to the safety and effectiveness of the treatment for your child) and under his/her supervision.